Read/Post Comments (0) | Recommended this article (0)
Please login to Zacks.com or register to post a comment.
Zacks' 7 Best Stocks
for June, 2013
FREE Report for Zacks.com
Visitors Only
Visitors Only
They're hand-picked from the list of Zacks Rank #1 Strong Buys. Our experts predict that their prices will jump the soonest.
Today, you can see them free.
- Latest News
- Most Popular
- 3 Top-Ranked Consumer ETFs to Buy Now
- This Week's Top Value Stocks
- RTI: When Will We Finally See a Pullback?
- RTI: When is the Fed's "Taper Telegraph" Coming?
- Insurance Industry Stock Outlook - May 2013
- Top Stocks with Big Potential Catch-Up Moves
- Roundtable Top Picks of the Week
- Anatomy of Success: Green Mountain Coffee
- The Mega-Rally Rolls On
- Biotechnology ETF Investing 101
- AWS 5/21: The Beginning of the End for QE
Recent Quotes
| No Recent Quote currently available |
My Portfolio
|
My Portfolio Tracker One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today. |
More Zacks Resources
Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.
Zacks #1 Stocks on the Move 05/21/2013
| Company Name | Symbol | %Change |
|---|---|---|
| SCIENTIFIC L | SCIL | 8.00% |
| NATUS MEDICA | BABY | 6.11% |
| SUMMER INFAN | SUMR | 6.02% |
| RADIANT LOGI | RLGT | 5.32% |
| NEW ORIENTAL | EDU | 4.51% |
Quick Links
Resources
Client Support
Zacks Research is Reported On:
Zacks Investment Research
is an A+ Rated BBB
Accredited Business.
Copyright 2013 Zacks Investment Research
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm.
Visit performance for information about the performance numbers displayed above.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext. 9339.
Cubist Pharmaceuticals Inc. ( CBST - Analyst Report ) is all set to report its third quarter 2012 results on October 18, 2012. The Zacks Consensus Estimate for the third quarter is 45 cents, representing a year-over-year increase of 35.26%.
Second quarter 2012 recap
Cubist Pharma’s second quarter 2012 earnings (excluding special items but including stock-based compensation expense) came in at 68 cents per share, up 28.3% from the year-ago period.
Reported earnings came in at 58 cents compared with a loss of 34 cents in the year-ago quarter. The earnings results comfortably surpassed the Zacks Consensus Estimate of 48 cents. Results in the quarter were primarily driven by strong sales of antibiotic injection, Cubicin (daptomycin) in the US.
Revenue in the second quarter of 2012 climbed 30.0% to $230.6 million, beating the Zacks Consensus Estimate of $226.0 million.
Agreement of Estimate Revisions
Over the past seven days, most analysts covering Cubist Pharma have left their earnings estimates for the third quarter 2012 unchanged. The last seven days has seen only one analyst revising the earnings estimate for the third quarter of 2012. The movement has been in the upward direction. Similarly, the fiscal 2012 earnings estimate has been revised upwards by one analyst over the last seven days.
We believe that most analysts have preferred to adopt a wait-and-watch approach until Cubist Pharma unfurls its results on October 18 before revising their estimates. We expect Cubist Pharma’s results in the third quarter of 2012 to be driven by strong sales of Cubicin. We are also pleased by the company’s agreement with Optimer Pharmaceuticals Inc. ( OPTR - Analyst Report ) to co-promote Dificid in the US for C. difficile acquired diarrhea.
Magnitude of Estimate Revisions
Given the lack of significant directional pressure, earnings estimates for the third quarter and fiscal 2012 have gone up by a penny and 2 cents to 45 cents and $1.86 per share, respectively, over the last seven days.
Our Recommendation
Currently, we have a Neutral recommendation on Cubist Pharma. The stock carries a Zacks #3 Rank (Hold rating) in the short run.
Read the full reports :
Analyst Report on CBST
Analyst Report on OPTR